Join us on 13 November for our autumn hybrid event in London. This event will consist of an in-person seminar in London, which will also be streamed live (and recorded), allowing members to watch virtually.
Each company will present for 25 minutes and then take your questions for another 15 minutes. All attendees (whether attending in-person or virtually) will be able to ask questions and those attending the seminar will be able to network with company directors and fellow investors over drinks and a buffet.
Please register to attend the event in-person or to watch virtually, using the 2 different links below.
Click here to register for the in-person seminar in London.
Click here to join the virtual event.
Event registration opens at 4.30 pm and presentations commence at 5.00 pm.
There will be a Networking after the presentations.
Companies Presenting
Bioventix (BVXP)
Bioventix creates, manufactures and supplies high affinity sheep monoclonal antibodies (SMAs) for use in diagnostic applications. Bioventix antibodies are preferred for use when they confer an improved test performance compared to other available antibodies.
Most of Bioventix’s antibodies are used on blood-testing machines installed in hospitals and other laboratories around the world. Bioventix makes antibodies using its SMA technology for supply to diagnostic companies for subsequent manufacture into reagent packs used on blood-testing machines. These blood-testing machines are supplied by large multinational in vitro diagnostics (IVD) companies such as Roche Diagnostics, Siemens Healthineers, Abbott Diagnostics & Beckman Coulter. Antibody-based blood tests are used to help diagnose many different conditions including, amongst others, heart disease, thyroid function, fertility, infectious disease and cancer.
Presenter:
Peter Harrison- CEO
Peter is 65 years old and has ~30 years’ experience of antibody technology at Celltech, KS Biomedix & Bioventix.
TheraCryf plc (TCF)
TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders (*orphan indication).
Its strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has industry partnerships with companies including Stalicla SA, in neurodevelopmental disorders.
Presenters:
Dr Huw Jones, CEO
Huw has over 30 years’ experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on preclinical and clinical drug development, dilutive and non-dilutive financing and business development. Most recently he was a Non-executive Director of Ixaka Ltd and Chairman of Chronos Therapeutics Ltd. Huw is a non-executive Director of biotech industry body OBN. Huw holds a PhD in pharmacology from the University of Birmingham, UK
Toni Haenninen, CFO
Toni has over 20 years’ experience in business development and senior finance roles in both public and private companies, working in mature and emerging markets particularly in Europe and the USA where he has accomplished successful fundraises, transactions and fiscal management in the sector. He was previously CFO at Faron Pharmaceuticals Ltd., an AIM and Nasdaq First North listed clinical stage biopharmaceutical company based in the Finland and the US developing novel treatments for medical conditions with significant unmet needs. Toni has an MBA from the Helsinki School of Economics (currently Aalto University).